Literature DB >> 17962382

Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene.

Nitzan Levy1, Dierdre Tatomer, Candice B Herber, Xiaoyue Zhao, Hui Tang, Toby Sargeant, Lonnele J Ball, Jonathan Summers, Terence P Speed, Dale C Leitman.   

Abstract

Estrogen receptors (ERs) regulate gene transcription by interacting with regulatory elements. Most information regarding how ER activates genes has come from studies using a small set of target genes or simple consensus sequences such as estrogen response element, activator protein 1, and Sp1 elements. However, these elements cannot explain the differences in gene regulation patterns and clinical effects observed with estradiol (E(2)) and selective estrogen receptor modulators. To obtain a greater understanding of how E(2) and selective estrogen receptor modulators differentially regulate genes, it is necessary to investigate their action on a more comprehensive set of native regulatory elements derived from ER target genes. Here we used chromatin immunoprecipitation-cloning and sequencing to isolate 173 regulatory elements associated with ERalpha. Most elements were found in the introns (38%) and regions greater than 10 kb upstream of the transcription initiation site (38%); 24% of the elements were found in the proximal promoter region (<10 kb). Only 11% of the elements contained a classical estrogen response element; 23% of the elements did not have any known response elements, including one derived from the naked cuticle homolog gene, which was associated with the recruitment of p160 coactivators. Transfection studies found that 80% of the 173 elements were regulated by E(2), raloxifene, or tamoxifen with ERalpha or ERbeta. Tamoxifen was more effective than raloxifene at activating the elements with ERalpha, whereas raloxifene was superior with ERbeta. Our findings demonstrate that E(2), tamoxifen, and raloxifene differentially regulate native ER-regulatory elements isolated by chromatin immunoprecipitation with ERalpha and ERbeta.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17962382      PMCID: PMC2234590          DOI: 10.1210/me.2007-0340

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  52 in total

1.  Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites.

Authors:  R V Weatherman; N J Clegg; T S Scanlan
Journal:  Chem Biol       Date:  2001-05

2.  Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.

Authors:  Jason S Carroll; Alexander Swarbrick; Elizabeth A Musgrove; Robert L Sutherland
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

3.  Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription.

Authors:  Y Shang; X Hu; J DiRenzo; M A Lazar; M Brown
Journal:  Cell       Date:  2000-12-08       Impact factor: 41.582

4.  Molecular determinants for the tissue specificity of SERMs.

Authors:  Yongfeng Shang; Myles Brown
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

5.  Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes in vivo by estrogen receptor.

Authors:  Darya Burakov; Linda A Crofts; Chao-Pei Betty Chang; Leonard P Freedman
Journal:  J Biol Chem       Date:  2002-03-13       Impact factor: 5.157

6.  Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells.

Authors:  Leslie C Hodges; Jennifer D Cook; Edward K Lobenhofer; Leping Li; Lee Bennett; Pierre R Bushel; C Marcelo Aldaz; Cynthia A Afshari; Cheryl Lyn Walker
Journal:  Mol Cancer Res       Date:  2003-02       Impact factor: 5.852

7.  Estradiol represses human T-cell leukemia virus type 1 Tax activation of tumor necrosis factor-alpha gene transcription.

Authors:  Christina Tzagarakis-Foster; Romas Geleziunas; Abderrahim Lomri; Jinping An; Dale C Leitman
Journal:  J Biol Chem       Date:  2002-09-16       Impact factor: 5.157

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  TRANSFAC: transcriptional regulation, from patterns to profiles.

Authors:  V Matys; E Fricke; R Geffers; E Gössling; M Haubrock; R Hehl; K Hornischer; D Karas; A E Kel; O V Kel-Margoulis; D-U Kloos; S Land; B Lewicki-Potapov; H Michael; R Münch; I Reuter; S Rotert; H Saxel; M Scheer; S Thiele; E Wingender
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

10.  Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor.

Authors:  Alex Yick-Lun So; Christina Chaivorapol; Eric C Bolton; Hao Li; Keith R Yamamoto
Journal:  PLoS Genet       Date:  2007-06       Impact factor: 5.917

View more
  18 in total

Review 1.  Nuclear receptor location analyses in mammalian genomes: from gene regulation to regulatory networks.

Authors:  Geneviève Deblois; Vincent Giguère
Journal:  Mol Endocrinol       Date:  2008-02-21

2.  Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.

Authors:  Lonnele J Ball; Nitzan Levy; Xiaoyue Zhao; Chandi Griffin; Mary Tagliaferri; Isaac Cohen; William A Ricke; Terence P Speed; Gary L Firestone; Dale C Leitman
Journal:  Mol Cell Endocrinol       Date:  2008-11-18       Impact factor: 4.102

Review 3.  HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.

Authors:  Frank E Jones
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-13       Impact factor: 2.673

4.  The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression.

Authors:  Zhenzhen Tu; Hui Li; Yuxiang Ma; Bin Tang; Junmei Tian; Walter Akers; Samuel Achilefu; Yueqing Gu
Journal:  Mol Cell Biochem       Date:  2012-04-04       Impact factor: 3.396

5.  Identification of a functional antioxidant response element within the eighth intron of the human ABCC3 gene.

Authors:  Mark J Canet; Matthew D Merrell; Bryan G Harder; Jonathan M Maher; Tongde Wu; Andrew J Lickteig; Jonathan P Jackson; Donna D Zhang; Masayuki Yamamoto; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-10-27       Impact factor: 3.922

6.  Estrogen receptor β potentiates the antiproliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells.

Authors:  Zhenzhen Tu; Yuxiang Ma; Junmei Tian; Hui Li; Walter Akers; Samuel Achilefu; Yueqing Gu
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-08       Impact factor: 4.553

Review 7.  Estrogen receptor-beta and breast cancer: translating biology into clinical practice.

Authors:  Yuet-Kin Leung; Ming-Tsung Lee; Hung-Ming Lam; Pheruza Tarapore; Shuk-Mei Ho
Journal:  Steroids       Date:  2012-03-29       Impact factor: 2.668

8.  Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter.

Authors:  Stephanie J Ellison-Zelski; Natalia M Solodin; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2009-07-20       Impact factor: 4.272

9.  Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist.

Authors:  Jennifer E Mersereau; Nitzan Levy; Richard E Staub; Scott Baggett; Tatjana Zogovic; Tetjana Zogric; Sylvia Chow; William A Ricke; Mary Tagliaferri; Isaac Cohen; Leonard F Bjeldanes; Dale C Leitman
Journal:  Mol Cell Endocrinol       Date:  2007-11-26       Impact factor: 4.102

10.  Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists.

Authors:  Sreenivasan Paruthiyil; Aleksandra Cvoro; Xiaoyue Zhao; Zhijin Wu; Yunxia Sui; Richard E Staub; Scott Baggett; Candice B Herber; Chandi Griffin; Mary Tagliaferri; Heather A Harris; Isaac Cohen; Leonard F Bjeldanes; Terence P Speed; Fred Schaufele; Dale C Leitman
Journal:  PLoS One       Date:  2009-07-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.